摘要
目的:探讨Prospero相关同源异形盒蛋白1(PROX1)在宫颈癌组织中的表达及其临床意义。方法:用免疫组化染色法检测81例宫颈癌组织及其配对的癌旁组织中PROX1的表达水平。根据免疫组化染色结果将患者分为高表达组和低表达组,比较两组临床病理特征及生存预后。结果:癌组织中PROX1表达率为69.14%(56/81),明显高于癌旁组织表达率11.11%(9/81),差异有统计学意义(P<0.001)。高表达组组织低分化、深浸润和淋巴结转移率均高于低表达组(均P<0.05)。肿瘤低分化、浸润较深、淋巴结转移、未辅助化疗、PROX1高表达是宫颈癌患者不良生存预后的独立影响因素(均P<0.05)。高表达组5年生存率为40.74%,明显低于低表达组的71.73%(P<0.05)。结论:PROX1与宫颈癌的发生及发展有关,并且对生存预后的评估有一定价值。
Objective:To investigate the expression and clinical significance of Prospero-related homeobox 1(PROX1)in cervical cancer.Methods:Immunohistochemical staining was used to detect the expression of PROX1 in 81 cervical cancer tissues and adjacent tissues.Patients were divided into PROX1 high expression group and PROX1 low expression group,the differences of clinical-pathological characteristics and survival prognosis were compared between the two groups according to the staining performance.Results:The ratio of PROX1 expressed in cancer tissues was 69.14(56/81),which was significantly higher than adjacent tissues 11.11%(9/81)(P<0.05).The poor differentiation,deep invasion and metastatic lymph node ratio of PROX1 high expression group were significantly higher than those of PROX1 low expression group(P<0.05),poor differentiation,deep invasion,lymph node metastasis,no adjuvant chemotherapy and higher expression of PROX1 were the independent influence factors in the process of cervical cancer(P<0.05).The 5-year survival rate of the PROX1 high expression group was 40.74%,which was lower than 71.73%of PROX1 low expression group(P<0.05).Conclusion:PROX1 is associated with cervical cancer oncogenesis and development,and PROX1 has a certain value to evaluate the outcomes of cervical cancer patients.
作者
李冰
马起鹏
林林
刘畅
LI Bing;MA Qipeng;LIN Lin;LIU Chang(Department of Obstetrics and Gynecology, Tieling Central Hospital,Tieling 112000, China;Department of Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110022, China)
出处
《东南大学学报(医学版)》
CAS
2021年第3期376-380,共5页
Journal of Southeast University(Medical Science Edition)
基金
沈阳市科学技术计划项目(17-230-6-50)。